The estimated Net Worth of Ross Haghighat is at least $8.91 Million dollars as of 16 September 2019. Mr. Haghighat owns over 55,539 units of Aduro BioTech stock worth over $8,581,517 and over the last 10 years he sold ADRO stock worth over $219,728. In addition, he makes $111,448 as Independent Director at Aduro BioTech.
Sign up
Mr. Haghighat ADRO stock SEC Form 4 insiders trading
Ross has made over 3 trades of the Aduro BioTech stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 55,539 units of ADRO stock worth $35,545 on 16 September 2019.
The largest trade he's ever made was exercising 55,539 units of Aduro BioTech stock on 16 September 2019 worth over $35,545. On average, Ross trades about 5,363 units every 80 days since 2015. As of 16 September 2019 he still owns at least 87,122 units of Aduro BioTech stock.
You can see the complete history of Mr. Haghighat stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ross Haghighat biography
Ross Haghighat serves as Independent Director of the Company. Mr. Haghighat has served as a member of our Board of Directors since 2009. Mr. Haghighat is the founder, Chairman and Managing Partner of Triton Systems, Inc. Mr. Haghighat has served on the board of Triton Systems, Inc., a product venturing company, where he has also served as its Chief Executive Officer since 2009. Additionally, Mr. Haghighat has served on the board of directors of S12 Technologies and FRX Polymers since 2009. Mr. Haghighat holds a Bachelor’s of Science and a Masters in Material Science, Organometallic Chemistry from Rutgers University and a Master of Business Administration from Boston College. Because of his extensive experience in the biotechnology field, we believe Mr. Haghighat is able provide valuable contributions to our Board of Directors.
What is the salary of Ross Haghighat?
As the Independent Director of Aduro BioTech, the total compensation of Ross Haghighat at Aduro BioTech is $111,448. There are 1 executives at Aduro BioTech getting paid more, with William Greenman having the highest compensation of $120,948.
How old is Ross Haghighat?
Ross Haghighat is 56, he's been the Independent Director of Aduro BioTech since 2009. There are 1 older and 3 younger executives at Aduro BioTech. The oldest executive at Aduro BioTech, Inc. is Eric Bjerkholt, 60, who is the Chief Financial Officer.
What's Ross Haghighat's mailing address?
Ross's mailing address filed with the SEC is C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY, CA, 94710.
Insiders trading at Aduro BioTech
Over the last 10 years, insiders at Aduro BioTech have traded over $5,295,750 worth of Aduro BioTech stock and bought 614,134 units worth $10,440,278 . The most active insiders traders include William Mariner Greenman, Stephen T Isaacs, and Thomas W. Dubensky. On average, Aduro BioTech executives and independent directors trade stock every 11 days with the average trade being worth of $2,189,064. The most recent stock trade was executed by Stephen T Isaacs on 15 September 2020, trading 32,481 units of ADRO stock currently worth $77,630.
What does Aduro BioTech do?
Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.
What does Aduro BioTech's logo look like?
Complete history of Mr. Haghighat stock trades at Aduro BioTech
Aduro BioTech executives and stock owners
Aduro BioTech executives and other stock owners filed with the SEC include:
-
William Greenman,
Independent Director -
Ross Haghighat,
Independent Director -
Eric Bjerkholt,
Chief Financial Officer -
Noopur Liffick,
IR Contact Officer -
Dolca Thomas,
Director -
Michelle Griffin,
Director -
Jerel Davis,
Director -
Srinivas Akkaraju,
Director -
Alan Glicklich,
Chief Medical Officer -
Tom Frohlich,
Chief Business Officer -
Eric Dobmeier,
President, Chief Executive Officer, Director -
Thomas W. Dubensky,
Chief Scientific Officer -
Gregory W Schafer,
Chief Operating Officer -
Natalie Sacks,
Chief Medical Officer -
Frank Mccormick,
Director -
Gerald Chan,
Director -
Stephen T Isaacs,
President and CEO -
Stephanie Monaghan O Brien,
Director -
Stephen A Sherwin,
Director -
Dirk G. Brockstedt,
Sr. VP of Research and Dev. -
Frank Karbe,
Director -
Elsas Andrea Van,
Chief Scientific Officer -
David Henry Mack,
Director -
Celeste Ferber,
SVP, GC and Secretary -
Dimitry Sa Nuyten,
Chief Medical Officer -
Jennifer Lew,
Sr. Vice President of Finance -
Venture (Vi) Investments Lt...,
10% owner -
John E. And Lois A. Rogers,
10% owner -
Keen Ltd Ultimate,
10% owner -
Blaine Templeman,
Chief Legal Officer -
James H Welch,
See Remarks -
William G Kachioff,
Interim CFO